Intragastric nitrites, nitrosamines, and bacterial overgrowth during cimetidine treatment

R W STOCKBRUGGER,* P B COTTON,† N EUGENIDES, B A BARTHOLOMEW, M J HILL, and C L WALTERS

From the Department of Gastroenterology, The Middlesex Hospital, London, the Central Public Health Laboratory, Bacterial Metabolism Research Laboratory, Colindale, London, and Leatherhead Food Research Association, Leatherhead, Surrey

SUMMARY A six week course of cimetidine (1 g/day) healed peptic ulcers in 20 of 23 patients (14 with duodenal ulcer, nine with gastric ulcer). Reduction of basal acid output by 73% and peak acid output by 36% led to a rise in concentrations of intragastric aerobic bacteria and nitrate-reducing bacteria. While the mean intragastric concentration of nitrate was unchanged by treatment, there were statistically significant rises in nitrite and N-nitrosamine concentrations. The conversion from nitrates to nitrites was closely related to the occurrence of nitrate-reducing bacteria. In three patients the intragastric milieu had returned to normal two months after cimetidine treatment had been discontinued. Mean nitrite and N-nitrosamine concentrations did not return to pre-treatment levels in the group of eight patients who remained on maintenance cimetidine (0.4 g at night-time) for three months after the full dose treatment. This study shows that cimetidine treatment can create an intragastric milieu resembling that of atrophic gastritis. Large scale and long-term studies are necessary to establish whether these findings have any clinical significance.

Cimetidine is effective in the treatment of peptic ulcers; as a result it is widely used, and is increasingly prescribed even in patients with no specific diagnosis. Some minor adverse effects have been described and there have been anecdotal reports about cimetidine delaying the diagnosis of gastric cancer. The most serious objection to the drug, however, is the suggestion that long-term use might lead to malignant transformation of the gastric mucosa.

There is an increased incidence of gastric dysplasia and gastric cancer in patients with atrophic gastritis with or without pernicious anaemia, and after gastric resection. Most of these patients have hypochlorhydria or achlorhydria, and intragastric bacterial overgrowth. Some of the intragastric bacteria are able to convert endo- and exogenous nitrates to nitrites, leading potentially to the synthesis of N-nitrosamines. These compounds are carcinogenic in experimental animals and could contribute to the development of malignancy in atrophic gastritis.

The present study was undertaken to see whether acid reduction by short-term and maintenance treatment with cimetidine can induce intragastric bacterial overgrowth with the formation of intraluminal nitrates and N-nitrosamines.

Methods

Patients Twenty-three patients with endoscopically proven peptic ulcers were admitted to the study, which had been approved by the Clinical Investigation Panel at The Middlesex Hospital. They were 18 men and five women; mean age 49 years, mean duration of ulcer disease six years; 15 patients were smokers and eight non-smokers; 14 had duodenal ulcers, nine gastric ulcers. In three of the patients with gastric ulcers, the ulcers were situated in the pre-pyloric region. Fourteen patients had never been treated for peptic ulcer disease; nine had previously received cimetidine but in seven at least 12 weeks had passed...
Intragastric nitrites, nitrosamines, and bacterial overgrowth during cimetidine treatment

since last medication. One patient was on maintenance treatment with 400 mg at night when she entered the study, and another patient had been treated with 1 g/day for one week, because of upper gastrointestinal bleeding, up to 24 hours before the first secretion test.

**SCHEDULE OF INVESTIGATIONS AND TREATMENT**

Within a few days of endoscopy, the patients underwent a gastric secretion test and a collection of specimens for microbiology and biochemistry. Cimetidine treatment (200 mg tds before meals and 400 mg at night) was started immediately after these tests, and continued until they were repeated six weeks later. The repeat tests were undertaken in the morning in the fasting state, the patients having had 400 mg of cimetidine the previous night, and 200 mg two hours before the tests. Check endoscopy was performed, and patients with unhealed ulcers were excluded from further study.

Eleven patients with healed ulcers were randomly divided into two groups: group A, three patients were given cimetidine (400 mg at night) for one month only; nasogastric intubation was then repeated two months after cessation of treatment; group B, eight patients received longer maintenance treatment; seven with cimetidine (400 mg at night) for another three months, and one with 1 g/day for six months. A third nasogastric intubation for collection of gastric juice was performed on the morning after the last dose had been taken.

Twelve patients could not undergo maintenance treatment; three had unhealed ulcers; one had complicating disease, three were not examined for technical reasons, and five patients did not attend.

**TECHNICAL METHODS**

Specimens for microbiological and biochemical analysis were aspirated from the stomach after passing a sterile tube via the nose, and discarding the initial aspirate. This method was initially validated by taking specimens from the nostril and palate.

**Microbiology**

Specimens were transported without delay to the microbiology department; gastric contents were diluted with broth, and viable organisms were estimated by the Miles and Misra technique on blood agar and McConkey media, incubated aerobically at 37°C. Organisms were identified using standard techniques.

**Nitrate and nitrite analysis**

5 millilitres of gastric juice were buffered to pH 9-4 with 5% borax buffer. The sample was deproteinised using zinc acetate in acetic acid and potassium ferrocyanide solution. Alumina cream was used to remove the colour from the gastric juice, and nitrite was measured by means of the diazo compound formed between sulphanilic acid and N-1-naphthylethylene diamine di-HCl. Nitrate was determined after conversion to nitrite by incubating the deproteinised, decolourised gastric juice with a bacterial suspension of *E. coli* having high nitrate reductase activity.

**Nitrate-reducing bacteria** 0.5 ml of gastric juice was inoculated into 4-5 ml glycerol broth and frozen. Samples were stored at −20°C until bacteriological studies were carried out. Nitrate reducing activity was assessed by the method of Cowan and Steel, and the number of nitrate-reducing organisms was obtained by reference to 'mean probable number' tables.

**N-nitroso-compounds** Sulphamic acid was added at a concentration of 0.5% w/v to the residue of about 10 ml gastric juice, to prevent nitrosation as an artefact during storage. N-nitroso-compounds were extracted into ethyl-acetate from the acid milieu; thus any such compounds with a basic function are not included in the extraction. N-nitrosamines and N-nitrosamides were determined by the group selective procedures of Walters et al. in which such compounds are denitrosated selectively to nitric oxide for measurement using a chemiluminescence analyser. All types of N-nitroso-compounds have been found to respond to this procedure. Of the compounds potentially formed from nitrite and nitrate in a biological matrix only nitrolic acids and S-nitrothiols have also been found to yield nitric oxide under the same conditions as N-nitroso-compounds.

**Gastric secretion tests**

Gastric secretion tests were performed by standard technique. Small amounts of gastric juice were used to estimate the pH to the nearest half unit by pH-paper (Merck). Basal secretion was measured during four 15-minute periods and the maximal secretion for another hour after an intramuscular injection of pentagastrin (6 μg/kg body weight). Gastric acid output was expressed in the traditional terms of BAO/h and PAO/h after measuring volume and hydrogen ion concentration for each sample.

Statistical analysis of the data was performed using Student's *t* test for paired data and linear regression analysis.

**Results**

**HEALING OF ULCERS**

Ulcers had healed after six weeks' treatment in 20 of the 23 patients (13 of 14 with duodenal ulcer, and
seven of nine with gastric ulcer). Eleven of the patients with healed ulcers were placed on maintenance treatment.

REDUCTION OF ACID OUTPUT
The pH of the first basal gastric sample rose from 1.76±0.21 (mean ± SEM) before treatment, to 5.34±0.43 after treatment (p<0.001) (Table 1). Reduction of basal acid output (BAO) was 73% (p<0.001) and of peak acid output (PAO) 36% (p<0.001) for all patients. Reductions for duodenal ulcers were: BAO 79% (p<0.001), PAO 31% (p<0.001), and for gastric ulcers were: BAO 61% (p<0.01), PAO 43% (p<0.001). The three patients whose ulcers did not heal showed a reduction of BAO and PAO similar to that in the patients whose ulcers healed.

BACTERIAL OVERGROWTH AND CHANGES IN NITRATES, NITRITES, AND N-NITROSAMINES
The mean concentration of bacteria (per ml gastric juice) before treatment was log₁₀ 0.82±0.68 SEM for all patients and had risen significantly to log₁₀ 4.91±0.59 after treatment (p<0.001) (Table 1).

After six weeks of cimetidine 1 g/day four patients had sterile gastric juice in the fasting state. Fourteen of the remaining 19 patients had intragastric growth of upper respiratory tract flora only (including Staphylococcus aureus, Streptococcus viridans, Staphylococcus epidermis, Neisseria spuria); five patients had an intragastric flora of faecal type either alone or in combination with upper respiratory tract flora. Intragastric growth of candida was found in four of 23 patients (ranging from log₁₀ 3.84 to 4.28). None of the patients reported symptoms which could be related to bacterial or fungal overgrowth.

There was a close correlation between bacterial counts and basal pH (r=0.822, p<0.001) and with BAO (r=0.664, p<0.001) but no correlation with PAO (r=0.402, p>0.05).

The rise in concentration of total aerobic bacteria was paralleled by a significant rise in the number of nitrate-reducing bacteria (Table 1). The correlation between total bacteria/ml and those capable of nitrate-reduction was significant (r=0.631, p<0.01) (Fig. 1).

The mean concentration of nitrates did not fall significantly during treatment, but there was a significant rise for nitrates in the total group of patients; the rise in the group of patients with gastric ulcers was not significant (Table 2).

There was a significant correlation between the concentration of nitrate-reducing bacteria and the ratio of nitrates to the total of nitrates plus nitrates (Fig. 2). Treatment also induced a significant increase in the N-nitrosamine concentrations for the total patient group and for the subgroup of patients with gastric ulcers; the rise in the subgroup of patients with duodenal ulcers was not significant (Table 2).

MAINTENANCE TREATMENT
Complete gastric secretion tests were not repeated in the 11 patients given any maintenance treatment; instead, the pH of a basal specimen of gastric juice was measured, and specimens were prepared for microbiological and biochemical analyses as described above.

In the three patients in whom maintenance treatment had been discontinued two months before re-examination (group A), the pH, bacterial concentrations, and levels for nitrates had returned to pre-treatment values, but two nitrosamine-levels were still raised (52 and 120 μg/l as NN pyrrol respectively). In the eight patients on three months' maintenance treatment (group B), the mean basal pH had fallen from 6.7±0.4 to 4.5±0.9 (p<0.02). Mean counts of nitrate-reducing bacteria (Fig. 3a) and concentrations of nitrate, nitrite, (Fig. 3b) and N-nitrosamines (Fig. 3c) were not, however, statistically significantly different from those after full dose treatment.

Table 1 Gastric pH and bacterial counts (mean ± SEM) in 23 patients with peptic ulcers before and after six weeks of cimetidine treatment

<table>
<thead>
<tr>
<th></th>
<th>All patients n=23</th>
<th>Duodenal ulcer n=14</th>
<th>Gastric ulcer n=9</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH</td>
<td>Before 1.76±0.21</td>
<td>1.57±0.09</td>
<td>2.07±0.55</td>
</tr>
<tr>
<td></td>
<td>p&lt;0.001</td>
<td>p&lt;0.001</td>
<td>p&lt;0.01</td>
</tr>
<tr>
<td></td>
<td>After 5.34±0.43</td>
<td>5.35±0.53</td>
<td>5.33±0.82</td>
</tr>
<tr>
<td>Total aerobic bacteria</td>
<td>Before 0.82±0.68</td>
<td>0.11±0.01</td>
<td>1.93±1.07</td>
</tr>
<tr>
<td>(log₁₀/ml gastric juice)</td>
<td>p&lt;0.001</td>
<td>p&lt;0.001</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>After 4.91±0.59</td>
<td>5.59±0.55</td>
<td>3.85±1.03</td>
</tr>
<tr>
<td>Nitrate-reducing bacteria</td>
<td>Before 0.29±0.23</td>
<td>0.10±0.10</td>
<td>0.61±0.21</td>
</tr>
<tr>
<td>(log₁₀/ml gastric juice)</td>
<td>p&lt;0.001</td>
<td>p&lt;0.01</td>
<td>p&lt;0.05</td>
</tr>
<tr>
<td></td>
<td>After 2.67±0.54</td>
<td>2.97±0.72</td>
<td>2.12±0.75</td>
</tr>
</tbody>
</table>
Intragastric nitrites, nitrosamines, and bacterial overgrowth during cimetidine treatment

Discussion

This study confirms that cimetidine is a potent inhibitor of basal and stimulated gastric acid output; the ulcer healing rate of 87% after treatment with 1 g/day for six weeks is comparable with other reports. Parallel to the reduction in acid output, we showed a marked alteration of the intragastric milieu. There was a significant rise in bacterial concentrations; some of the bacterial species were capable of reducing nitrates to nitrites, and we found statistically significant increases in nitrite and N-nitrosamine concentrations after short-term treatment.

Our samples were taken in the morning, in the fasting state. Despite suggestions to the contrary, the values probably reflect the situation throughout the night. Bacterial counts of more than 10^5 organisms/ml in the upper gastrointestinal tract have been judged to be pathological. Some, however, would regard such bacterial overgrowth to be significant only if it includes faecal type organisms, whose presence indicates that a resident flora has been established and that the juice is not bacteriocidal at any time during the day or night. An overgrowth of faecal type organisms is seen in most patients with achlorhydria due to atrophic gastritis, and was observed in four of our patients after cimetidine treatment. Our documented increases in N-nitroso compounds after

Table 2  Intragastric concentrations (mean ± SEM) of nitrate, nitrite, and N-nitrosamine before and after six weeks of cimetidine treatment

<table>
<thead>
<tr>
<th></th>
<th>No.</th>
<th>All patients</th>
<th>Duodenal ulcer</th>
<th>Gastric ulcer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nitrates (μmol/l)</strong></td>
<td>22</td>
<td>Before 313±39</td>
<td>339±51</td>
<td>268±56</td>
</tr>
<tr>
<td></td>
<td></td>
<td>After 272±36</td>
<td>278±74</td>
<td>260±75</td>
</tr>
<tr>
<td><strong>Nitrites (μmol/l)</strong></td>
<td>22</td>
<td>Before 3.2±1.7</td>
<td>1.6±0.7</td>
<td>5.9±4.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>After 52.1±21.9</td>
<td>52.0±20.8</td>
<td>16.3±7.8</td>
</tr>
<tr>
<td><strong>N-nitrosamines (μg/1 NN-pyrrol)</strong></td>
<td>20</td>
<td>Before 14.1±3.7</td>
<td>15.9±4.8</td>
<td>10.9±5.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>After 26.3±3.4</td>
<td>23.7±4.1</td>
<td>31.1±5.3</td>
</tr>
</tbody>
</table>
Fig. 3 Results in eight patients treated with cimetidine 1 g/day for six weeks and thereafter with 0.4 g at night for a further 12 weeks. (a) nitrate-reducing bacteria (b) nitrates, (c) N-nitrosamines (boxes indicate mean ± SEM).
Cimetidine treatment must be assumed to result from nitrite produced by bacterial action; the assay did not include N-nitroso-cimetidine and other compounds with a basic function.

The clinical significance of these changes is open to speculation. The role of N-nitrosamines in human gastric cancer remains to be established. The rises seen in this study were relatively small, and the mean level after treatment remained within the pre-treatment range; only a few values exceeded those earlier obtained in normal subjects in the same laboratory. They were, however, similar to those found using an identical technique in a small number of patients with pernicious anaemia, who do have an increased risk of gastric cancer (in preparation). There is also a parallel with patients who have undergone surgical treatment for peptic ulceration, which can result in intragastric conditions similar to those seen after treatment with cimetidine in full dosage. The increased risk of gastric cancer in such patients does not appear until about 10 years have passed.

Full dose treatment with cimetidine is usually given for short courses. Our results in a small number of patients have not contraindicated such use with good clinical indications. Many patients are now prescribed low dose maintenance treatment with cimetidine. It is of concern that the mean N-nitrosamine levels remained raised in this study after three months' maintenance treatment at lower dosage, and even two months after the end of treatment in two patients. These aspects require longer term and larger scale studies before any clinical conclusions can be attempted.

We are pleased to acknowledge support from Smith Kline and French (England), the Special Trustees of the Middlesex Hospital, and the Cancer Research Campaign.

References

25 Metz G, Gassull MA, Drasar BS, Jenkins DJA, Blends LM. Breath hydrogen test for small intestinal
Intragastric nitrites, nitrosamines, and bacterial overgrowth during cimetidine treatment.

R W Stockbrugger, P B Cotton, N Eugenides, B A Bartholomew, M J Hill and C L Walters

Gut 1982 23: 1048-1054
doi: 10.1136/gut.23.12.1048

Updated information and services can be found at:
http://gut.bmj.com/content/23/12/1048

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Ulcer (484)
Stomach and duodenum (1689)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/